Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs: results of the GO-MORE study

OBJECTIVES: To evaluate the efficacy and safety of subcutaneous golimumab as add-on therapy in patients with active rheumatoid arthritis (RA) despite disease-modifying antirheumatic drug (DMARD) treatment. To evaluate an intravenous plus subcutaneous (IV+SC) golimumab strategy in patients who had no...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Combe, Bernard, Dasgupta, Bhaskar, Louw, Ingrid, Pal, Sarvajeet, Wollenhaupt, Jürgen, Zerbini, Cristiano A F, Beaulieu, Andre D, Schulze-Koops, Hendrik, Durez, Patrick, Yao, Ruji, Vastesaeger, Nathan, Weng, Haoling H
Format: Artigo
Jezik:Inglês
Izdano: BMJ Publishing Group 2014
Teme:
Clinical and Epidemiological Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4112444/
https://ncbi.nlm.nih.gov/pubmed/23740226
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/annrheumdis-2013-203229
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items